Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

BACKGROUND: The open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer (mCRPC) who had previously received docetaxel. METHODS: Patients (n = 507) received...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Prostate
Glavni autori: Joshua, Anthony M., Shore, Neal D., Saad, Fred, Chi, Kim N., Olsson, Carl A., Emmenegger, Urban, Scholz, Mark, Berry, William, Mukherjee, Som D., Winquist, Eric, Haas, Naomi B., Foley, Margaret A., Dmuchowski, Carl, Perabo, Frank, Hirmand, Mohammad, Hasabou, Nahla, Rathkopf, Dana
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2015
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5024054/
https://ncbi.nlm.nih.gov/pubmed/25683285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22965
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items